Catalent
NEWS
Several biopharma companies have adjusted their leadership teams to include new chief executive officers who are expected to guide the companies and their programs into the future.
A U.S. Congress subcommittee unanimously approved the ACT for ALS bill in a decision that could soon pour massive funding into the search for treatment for this debilitating and deadly disease.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
Earlier this month, Catalent announced plans to add 500–600 jobs in Bloomington, Ind., one of its Moderna and Johnson & Johnson COVID-19 vaccine manufacturing sites.
Moderna, one of three companies to have a COVID-19 vaccine authorized in the U.S., isn’t resting on its accomplishments but is instead working to scale up production further and improve on its vaccine.
CDMO Catalent continues its push to the top with yet another acquisition. Buying out Delphi Genetics, the manufacturing company can now add plasmid DNA production to its growing list of offerings.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
The pharmaceutical supply chain is being pushed to its limit as it prepares to deliver COVID-19 vaccines and therapeutics to the entire world as soon as possible, while continuing to produce and deliver all the usual medications and products.
With Moderna on the precipice of launching its Phase III trial of 30,000 people for its COVID-19 vaccine, mRNA-1273, it is ramping up manufacturing capabilities.
JOBS
IN THE PRESS